UCL Discovery Stage
UCL home » Library Services » Electronic resources » UCL Discovery Stage

The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients

Wareham, NE; Mocroft, A; Sengeløv, H; Da Cunha-Bang, C; Gustafsson, F; Heilmann, C; Iversen, M; ... MATCH in PERSIMUNE study group; + view all (2018) The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients. Journal of Cancer Research and Clinical Oncology , 144 (8) pp. 1569-1580. 10.1007/s00432-018-2674-9. Green open access

[thumbnail of Mocroft EBVDNAemia and PTLD_clean version_June18.pdf]
Preview
Text
Mocroft EBVDNAemia and PTLD_clean version_June18.pdf - Accepted Version

Download (542kB) | Preview

Abstract

PURPOSE: Emerging EBV DNAemia in plasma is considered an early sign of post-transplant lymphoproliferative disorder (PTLD). The aim of this study was to quantify the extent of benefit from screening for EBV DNAemia to detect emerging PTLD among solid organ (SOT) or hematopoietic stem cell transplant recipients (HSCT). METHODS: We used receiver operating characteristic (ROC) curves for assessing ability of models to predict PTLD. Among 2642 recipients transplanted between January 2004 and December 2014, 79 (3%) developed PTLD. RESULTS: EBV DNAemia was observed in 331/1784 recipients (18.6%, 95% CI 16.8-20.4) with measured EBV DNA. The area under the curve (AUC) of the ROC of EBV DNAemia to identify persons with subsequent PTLD was 72% (95% CI, 64-79%) among SOT and 59% (51-68%) among HSCT. Including clinical predictors such as age, gender, transplant year and type, high-risk EBV serostatus, and routine biochemistry in addition to EBV DNAemia increased AUC to 83% (75-90%) among SOT and 84% (79-89%) among HSCT. Among HSCT, including additional factors such as T-cell-depleting treatment, acute graft vs. host disease and donor match increased AUC to 85% (78-91%). CONCLUSIONS: We constructed a model to better predict PTLD compared to EBV DNA screening alone which could have clinical implications.

Type: Article
Title: The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients
Location: Germany
Open access status: An open access version is available from UCL Discovery
DOI: 10.1007/s00432-018-2674-9
Publisher version: https://doi.org/10.1007/s00432-018-2674-9
Language: English
Additional information: This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions.
Keywords: AUROC, DNA, EBV, PTLD, Transplantation
UCL classification: UCL
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences
UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Population Health Sciences > Institute for Global Health
URI: https://discovery-pp.ucl.ac.uk/id/eprint/10051405
Downloads since deposit
25,916Downloads
Download activity - last month
Download activity - last 12 months
Downloads by country - last 12 months

Archive Staff Only

View Item View Item